Table 1 Characteristics of patients receiving ESA therapy before and after the March 2007FDA black box warning
Entire study period | Base period | Follow up | P-value* | |
|---|---|---|---|---|
Number of patients months | 13,748,238 | 6,702,212 | 7,046,026 | |
% | % | % | ||
Age (Year) | <.0001 | |||
18–44 | 13.5 | 13.6 | 13.4 | |
45–64 | 37.9 | 37.1 | 38.6 | |
≥65 | 48.6 | 49.3 | 48.0 | |
Race | 0.329 | |||
White | 54.6 | 54.6 | 54.6 | |
Non-white | 45.4 | 45.4 | 45.4 | |
Gender | <.0001 | |||
Male | 53.7 | 53.4 | 53.9 | |
Female | 46.3 | 46.6 | 46.1 | |
Duration of dialysis | <.0001 | |||
<12 months | 20.3 | 21.2 | 19.5 | |
12– < 36 months | 29.5 | 29.9 | 29.2 | |
≥36 months | 50.1 | 48.9 | 51.3 | |
Diabetes co-morbidity | <.0001 | |||
Diabetic | 44.3 | 44.0 | 44.6 | |
Non-diabetic | 55.7 | 56.0 | 55.4 | |
Facility profit status | <.0001 | |||
For-profit | 81.2 | 80.5 | 82.0 | |
Non-profit | 18.8 | 19.5 | 18.0 | |
Facility chain status | <.0001 | |||
Chain 1 (FP) | 27.0 | 26.9 | 27.0 | |
Chain 2 (FP) | 30.4 | 26.8 | 33.9 | |
Chain 3 (NP) | 4.0 | 4.1 | 3.9 | |
Medium chain | 10.8 | 13.0 | 8.8 | |
Small/non chains | 17.8 | 18.7 | 16.9 | |
Hospital-based (NP) | 10.0 | 10.6 | 9.5 | |
Hematocrit value# | <.0001 | |||
<30% | 8.4 | 7.4 | 9.4 | |
30– < 36% | 45.7 | 41.6 | 49.8 | |
≥36% | 45.9 | 51.0 | 40.8 |